GYG1 Antibody [E16D17] | Primary Antibodies

Application: Reactivity: Human, Rat

Usage Information

Dilution
IHC1:100

Application
WB, IHC, ELISA

Reactivity
Human, Rat

Source
Mouse Monoclonal Antibody

Storage Buffer
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage (from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

Predicted MW Observed MW
39 kDa 50 kDa
^*Why do the predicted and actual molecular weights differ? The following reasons may explain differences between the predicted and actual protein molecular weight. Post-translational modifications(e.g., phosphorylation, glycosylation); Splice variants and isoforms; Relative charge; Multimerization.

Datasheet & SDS

Biological Description

Specificity
GYG1 Antibody [E16D17] detects endogenous levels of total GYG1 protein.

Clone
E16D17

Synonym(s)
Glycogenin-1, GN-1, GN1, GYG1, GYG

Background
GYG1 encodes glycogenin‑1, a self‑glucosylating glycosyltransferase that initiates cytosolic glycogen biogenesis by generating the short glucose primer required for subsequent elongation by glycogen synthase and branching enzyme. The protein belongs to the glycosyltransferase 8 family and contains a catalytic core that binds UDP‑glucose and an internal tyrosine residue that accepts the first glucose moiety, forming a covalent glucose 1‑O‑tyrosyl linkage from which an α‑1,4‑linked oligosaccharide chain is extended to a length of roughly 8–10 glucose residues, creating a minimal glycogen core particle. Glycogenin‑1 is highly expressed in skeletal muscle and heart, with lower levels in other tissues, and localizes to cytoplasmic glycogen granules where it remains at the center of mature glycogen particles, so the abundance and integrity of GYG1 directly influence the capacity of myofibers to establish and maintain normal glycogen stores for contraction‑linked energy demands. The autoglucosylation reaction of glycogenin‑1 uses UDP‑glucose as the donor substrate, and the generated primer is then handed off to glycogen synthase, which continues α‑1,4 chain elongation, and to the branching enzyme, which introduces α‑1,6 branch points, placing GYG1 at the top of the hierarchical enzymatic cascade that builds the branched glycogen polymer. Mutations in GYG1 that impair autoglucosylation, including substitutions of the essential tyrosine acceptor site or nearby residues, abolish primer formation and lead to glycogen storage disease type XV and related polyglucosan body myopathies, characterized by marked muscle glycogen depletion or abnormal glycogen structure, mitochondrial proliferation, and myopathic or cardiomyopathic phenotypes. Disease‑associated variants identified in patients include nonsense mutations and missense changes such as Thr83Met, which inactivate the glucosyltransferase activity and prevent the initiation of normal glycogen synthesis in skeletal muscle and, in some cases, heart, linking GYG1 defects to exercise intolerance, progressive muscle weakness, cardiomyopathy, and arrhythmias.

Background

GYG1 encodes glycogenin‑1, a self‑glucosylating glycosyltransferase that initiates cytosolic glycogen biogenesis by generating the short glucose primer required for subsequent elongation by glycogen synthase and branching enzyme. The protein belongs to the glycosyltransferase 8 family and contains a catalytic core that binds UDP‑glucose and an internal tyrosine residue that accepts the first glucose moiety, forming a covalent glucose 1‑O‑tyrosyl linkage from which an α‑1,4‑linked oligosaccharide chain is extended to a length of roughly 8–10 glucose residues, creating a minimal glycogen core particle. Glycogenin‑1 is highly expressed in skeletal muscle and heart, with lower levels in other tissues, and localizes to cytoplasmic glycogen granules where it remains at the center of mature glycogen particles, so the abundance and integrity of GYG1 directly influence the capacity of myofibers to establish and maintain normal glycogen stores for contraction‑linked energy demands. The autoglucosylation reaction of glycogenin‑1 uses UDP‑glucose as the donor substrate, and the generated primer is then handed off to glycogen synthase, which continues α‑1,4 chain elongation, and to the branching enzyme, which introduces α‑1,6 branch points, placing GYG1 at the top of the hierarchical enzymatic cascade that builds the branched glycogen polymer. Mutations in GYG1 that impair autoglucosylation, including substitutions of the essential tyrosine acceptor site or nearby residues, abolish primer formation and lead to glycogen storage disease type XV and related polyglucosan body myopathies, characterized by marked muscle glycogen depletion or abnormal glycogen structure, mitochondrial proliferation, and myopathic or cardiomyopathic phenotypes. Disease‑associated variants identified in patients include nonsense mutations and missense changes such as Thr83Met, which inactivate the glucosyltransferase activity and prevent the initiation of normal glycogen synthesis in skeletal muscle and, in some cases, heart, linking GYG1 defects to exercise intolerance, progressive muscle weakness, cardiomyopathy, and arrhythmias.

References
https://pubmed.ncbi.nlm.nih.gov/31791869/ https://pubmed.ncbi.nlm.nih.gov/20357282/

Reference Table for Selecting PVDF Membrane Pore Size Specifications

Protein Size (kDa)	PVDF Transfer Membrane Pore Size (μm)
< 10	0.22
10-20	0.22
20-30	0.45
30-45	0.45
45-70	0.45
80-100	0.45
100-140	0.45
> 140	0.45

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Protein Size (kDa)	Separating Gel Percentage
4-40	20%
12-45	15%
10-70	12.5%
15-100	10%
25-100	8%
60-210	5%